Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization.

Author(s)
Dong, Zhenyu; Noda, Kousuke; Kanda, Atsuhiro; Fukuhara, Junichi; Ando, Ryo; Murata, Miyuki; Saito, Wataru; Hagiwara, Masatoshi; Ishida, Susumu

Citation
Molecular vision, 19, 536-543

Issue Date
2013-03-05

Doc URL
http://hdl.handle.net/2115/54611

Type
article

File Information
Mol Vis_19_536-543.pdf

Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP
Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization

Zhenyu Dong,1,2 Kousuke Noda,1,2 Atsuhiro Kanda,1,2 Junichi Fukuhara,1,2 Ryo Ando,1,2 Miyuki Murata,1,2 Wataru Saito,1 Masatoshi Hagiwara,1 Susumu Ishida1,2

1Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 3Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Purpose: To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for attenuation of choroidal neovascularization (CNV) formation using a mouse model.

Methods: Laser photocoagulation was performed to induce CNV in C57BL/6J mice, followed by intravitreal injection of SRPIN340 or vehicle. Seven days after the treatment, the CNV size was evaluated using a flatmount technique. Protein levels of vascular endothelial growth factor (VEGF) and inflammation-associated molecules, such as monocyte chemottractant protein (MCP)-1 and intercellular adhesion molecule (ICAM)-1, in the retinal pigment epithelium-choroid complex were measured with enzyme-linked immunosorbent assay. Expression levels of total Vegf, exon 8a-containing Vegf isoforms, and F4/80 (a specific marker for macrophage) were assessed using real-time PCR.

Results: SRPIN340 inhibited CNV formation in a dose-dependent manner. Compared with the vehicle, SRPIN340 significantly decreased the protein levels of VEGF, MCP-1, ICAM-1, and consequently inhibited macrophage infiltration. Furthermore, SRPIN340 suppressed the gene expression levels of total Vegf and exon 8a-containing Vegf isoforms.

Conclusions: SRPIN340, a specific inhibitor of SRPK, suppressed Vegf expression and attenuated CNV formation. Our data suggest the possibility that SRPIN340 is applicable for neovascular age-related macular degeneration as a novel chemical therapeutics.

Age-related macular degeneration (AMD) is the primary cause of visual loss in developed countries [1-3]. In particular, neovascular AMD, characterized by choroidal neovascularization (CNV), is responsible for most cases of severe vision loss due to AMD [4,5]. CNV formation occurs through multifactorial processes involving the complex interaction of metabolic, genetic, and environmental factors. In particular, recent basic [6,7] and clinical [8-10] investigations have provided strong evidence that growth factors and cytokines, such as vascular endothelial growth factor (VEGF), play a pivotal role in the process of pathological angiogenesis.

The cytokine VEGF had long been considered a proangiogenic factor, but Bates and his colleagues identified antiangiogenic VEGF isoforms, VEGFxxxb (xxx denotes the number of amino acids), generated as a result of distal splice site selection in exon 8 (i.e., exon 8b) during alternative splicing of VEGF messenger RNA precursor (pre-mRNA) [11]. Pro- and antiangiogenic VEGF isoforms are generated from the same VEGF gene via alternative splicing of mRNA. The alternative splicing of VEGF pre-mRNA is regulated by splicing regulatory factors, including various serine/arginine-rich (SR) proteins [12]. Previous studies have shown that SR protein kinase (SRPK) activates SRSF1 (SF2/ASF) and SRSF5 (SRp40), both of which favor splicing site selection at exon 8a during the splicing of VEGF pre-mRNA, and consequently lead to upregulation of proangiogenic VEGF isoforms [13]. We have developed a specific inhibitor for SRPK, SRPIN340 [14], and inhibition of SRPK with SRPIN340 suppressed retinal angiogenesis by reducing the ratio of proangiogenic to total VEGF isoforms at the mRNA level [15]. In this study, we investigated the therapeutic effect of SRPIN340 on CNV using the laser photocoagulation model and found that SRPIN340 suppressed Vegf expression and attenuated CNV formation.

METHODS

Animals and induction of choroidal neovascularization: Eight-week-old C57BL/6J male mice (CLEA Japan, Tokyo, Japan) were used for this study. All animal experiments were approved by the Hokkaido University Animal Use Committee and conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Anesthesia was induced by intraperitoneal injection of pentobarbital (0.05 mg/g bodyweight), and pupils were dilated with...
topical 5% phenylephrine hydrochloride and 5% tropicamide. After anesthesia induction and pupil dilation, four laser spots were placed around the optic disc (532 nm, 200 mW power, 0.1 s, 75 μm spot size, Novus Spectra; Lumineis, Tokyo, Japan) using a slit-lamp delivery system with a cover glass as a contact lens. Laser spots with vitreous, retinal, or subretinal hemorrhage were excluded from the analysis.

**Serine/arginine-rich protein kinase inhibitor:** SRPIN340, an isonicotinamid compound, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl] (Figure 1), was found in a screening for chemicals specifically inhibiting SRPK to suppress the acute replication of viruses such as human immunodeficiency virus, using a scintillation proximity assay with a synthetic RS-repeat peptide as the substrate [16]. For SRPKs, SRPIN340 selectively inhibits SRPK1 and SRPK2 but does not inhibit other classes of SRPKs significantly, including Clk1 and Clk4 [14].

**SRPIN340 treatment:** SRPIN340 (50 mM in 100% dimethyl sulfoxide, DMSO) was diluted with phosphate buffered saline (PBS, potassium chloride, 2.68 mM; potassium phosphate monobasic, 1.47 mM; sodium chloride, 136.89 mM; sodium phosphate dibasic, 8.10 mM) to various concentrations in 0.1% DMSO before treatment. Mice were divided into five groups: CNV induction alone (the control group) and CNV induction with 1 μl intravitreal injection of either 0.1% DMSO, 0.2 pmol, 2 pmol, or 20 pmol SRPIN340. Intravitreal injection was performed using a 33-gauge needle (Extreme Microsyringe, Ito Corporation, Tokyo, Japan) immediately after laser photocoagulation.

**Measurement of choroidal neovascularization:** Seven days after laser injury, mice were euthanized with an overdose of anesthesia, performed by intraperitoneal injection with 2 mL of 5% pentobarbital sodium, and perfused with 5 mL PBS through the left ventricle, followed by 2.5 mL of 0.5% fluorescein-isothiocyanate-labeled dextran (Sigma-Aldrich, St. Louis, MO) in 1% gelatin. Subsequently, the eyes were enucleated and fixed with 2% paraformaldehyde for 30 min.

**Table 1. Primer sequences.**

| Gene                | Sequence (5'-3')                                                                 |
|---------------------|---------------------------------------------------------------------------------|
| Vegf                | F: AAGGAGAGCCAGA AGTCCCATGA R: CTCAATCGGACGGCAGTAGCT                            |
| Vegf containing exon 8a | F: GTTCAGAGCGGAGAAAGCAT R: TCACATCTGCAAGTACGTTCG                              |
| Actb                | F: CATCCGTA AAGACCTCTATGCCAAC R: ATGGAGCCACCGATCCACA                          |

Vegf, vascular endothelial growth factor; Actb, beta-actin
(Life Technologies). Actb was used as endogenous control. Threshold cycle (Ct) was determined automatically, and relative change in mRNA expression was calculated using the ΔΔCT values as previously reported [17]. All PCR reactions were repeated in triplicate, and the average values were used in the statistical analysis.

Quantification of infiltrating macrophages: Immunostaining of F4/80 was also performed to further quantify the infiltration of macrophages. Briefly, eyes were enucleated 3 days after the laser photocoagulation in combined with 1 μl intravitreal injection of either 0.1% DMSO or 20 pmol SRPIN340, and whole choroid-sclera complexes were incubated overnight at 4 °C with a rabbit polyclonal antibody against mouse CD31 (1:100 dilution; Abcam, Tokyo, Japan) and a rat polyclonal antibody against F4/80 (1:100 dilution; Serotec, Oxford, UK) as primary antibodies, respectively. Binding of primary antibody was localized with Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 546 goat anti-rat secondary antibody (1:200 dilution, respectively; Life Technologies). Finally, slides were mounted with Vectashield Mounting Medium (Vector Laboratories), and CNV was viewed with a fluorescence microscope (Biorevo, Keyence). The CD31-stained area of CNV and F4/80-positive macrophages were evaluated, and the area-adjusted number of macrophages per 1,000 μm² area of CNV was calculated.

Enzyme-linked immunosorbent assay: Four laser lesions were placed in each eye, and an intravitreal injection of either 1 μl of 0.1% DMSO or SRPIN340 was also administered. Protein levels of VEGF, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM)-1 in supernatant were determined using enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN) and normalized to total protein (BCA Protein Assay Kit, Thermo Scientific, Rockford, IL), according to the manufacturer’s protocols.

Statistics: Results are presented as mean±standard error of the mean (SEM). Statistical analysis was performed using the two-tailed unpaired Student t-test, and results were considered statistically significant when the p value was less than 0.05.
RESULTS

Impact of serine/arginine-rich protein kinase blockade during choroidal neovascularization formation: To determine whether SRPK blockade inhibits CNV formation, we quantified the CNV size in the flat mounts of the RPE-choroid complex with or without SRPIN340 administration. Seven days after laser injury, the animals treated with 2 pmol SRPIN340 (n=33; n represents the number of CNV lesions) showed a significant decrease in the average CNV size (19,870±1935 μm²), compared with the vehicle-treated animals (30,737±3758 μm², n=31, p<0.05; Figure 2A,B). Furthermore, a higher dose administration of SRPIN340 (20 pmol; n=23) significantly reduced the CNV size (15,649±1803 μm², p<0.01) to an even greater extent than that observed in the 2 pmol SRPIN340–treated animals, whereas a lower dose administration (0.2 pmol; n=17) did not significantly inhibit CNV formation (21,741±3695 μm², p=0.10; Figure 2A,B). No significant difference in CNV size was observed between mice subjected to laser injury alone and those subjected to laser and intravitreal injection of 0.1% DMSO or 20 pmol SRPIN340 (n=6 to 8 for real-time PCR analysis, n=8 to 10 for ELISA, respectively; n represents the number of eyes). *, p<0.05; †, p<0.01.

Impact of serine/arginine-rich protein kinase blockade on Veg f expression: To investigate the effect of SRPIN340 on Veg f isoforms, mRNA expression of total Veg f and Veg f isoforms containing exon 8a were analyzed using real-time PCR. Compared with mice treated with 0.1% DMSO (n=8; n represents the number of eyes), mRNA expression of total Veg f in the RPE-choroid complex obtained from CNV mice 3 days after laser photocoagulation with intravitreal injection of 0.1% DMSO or 20 pmol SRPIN340 (n=6 to 8 for real-time PCR analysis, n=8 to 10 for ELISA, respectively; n represents the number of eyes).*, p<0.05; †, p<0.01.
by 56% (p<0.05; Figure 3A). Similarly, mRNA expression of Vegf containing exon 8a was significantly decreased by 57% (p<0.05; Figure 3B). Furthermore, total VEGF concentration in mice treated with 20 pmol SRPIN340 (209.2±10.9 pg/mg, n=8) was significantly lower than mice treated with 0.1% DMSO (274.2±17.9 pg/mg, n=10, p<0.01; Figure 3C).

Suppression of adhesion molecules, inflammatory molecules, and macrophage influx by serine/arginine-rich protein kinase blockade: To explore the mechanism by which SRPIN340 suppresses CNV formation, concentrations of the inflammation-associated molecules MCP-1 and ICAM-1 in the RPE-choroid complex were measured. Levels of MCP-1 (19.5±0.9 pg/mg) and ICAM-1 (199.6±15.5 ng/mg) in the RPE-choroid complex of normal mice were significantly increased 3 days after laser photoagulation and intravitreal injection of 0.1% DMSO (MCP-1, 99.9±8.6 pg/mg, p<0.001; ICAM-1, 265.4±12.3 ng/mg, p<0.01, respectively). However, compared with mice treated with laser photoagulation and 0.1% DMSO, the protein levels of MCP-1 and ICAM-1 were significantly reduced in the RPE-choroid complex of the mice treated with laser photoagulation and 20 pmol SRPIN340 (MCP-1, 67.8±10.2 pg/mg, p<0.05; ICAM-1, 192.9±11.6 ng/mg, p<0.01, n=8-10, respectively; n represents the number of eyes, Figure 4A,B).

Furthermore, real-time PCR showed that mRNA expression of F4/80, the marker for mouse macrophages [18], was downregulated by 41% in the animals treated with 20 pmol SRPIN340 (n=6; n represents the number of eyes) compared to that of the vehicle-treated animals (n=8, p<0.05; Figure 5A). In accord with the real-time PCR data, suppression of macrophage influx by SRPIN340 was also depicted in the immunofluorescence study using F4/80 antibody. Compared with the vehicle-treated animals, the number of F4/80-positive macrophages in CNV lesions significantly decreased in the animals treated with 20 pmol SRPIN340 (15.5±4.0 and 6.5±1.8 /1000 μm², n=13 to 15, respectively; n represents the number of CNV lesions; p<0.05; Figure 5B,C).

DISCUSSION

To date, intravitreal injection of anti-VEGF agents has brought revolutionary changes to the treatment of neovascular AMD. Nevertheless, novel interventions for preventing and treating neovascular AMD remain to be developed because of possible ocular and/or systemic adverse events following long-term administration [19-23]. Discovery of antiangiogenic VEGF isoforms highlighted the importance and necessity of differentially targeting VEGF isoforms in treating neovascular AMD, and suggested the possibility of regulating the splicing of VEGF pre-mRNA as a therapeutic strategy. Small molecules and compounds, including SRPIN340, have currently shown promising results in targeting splicing factors and kinases involved in alternative splicing [14,24,25].

Most of the findings regarding the regulation of alternative splicing of VEGF pre-mRNA during pathological angiogenesis were obtained from in vitro study [13,15]. Using
in vitro experiments, upregulation of proangiogenic *VEGF* isoforms and simultaneous downregulation of antiangiogenic *VEGF* isoforms in various pathologies have subsequently been elucidated [26-29]. In contrast, animal experiments used in investigations of this mechanism are rarely reported. Moreover, a limited number of reports are currently available on the effect of specific inhibitors for SRPK against pathological angiogenesis such as a murine hypoxia-induced retinopathy model [15] and xenotransplanted tumor growth in nude mice [30]. Previous reports suggested that this suppressive effect was caused by the upregulation of antiangiogenic *VEGF* isoforms and the subsequent restoration of the balance between pro- and antiangiogenic *VEGF* isoforms. However, our data indicated that SRPIN340 suppressed total *Vegf* and *Vegf* isoforms containing exon 8a at the mRNA level. In addition, the total VEGF protein was also decreased by the SRPK inhibitor SRPIN340. Recently, Tripathi et al. reported that SRSF1 is a component of the 7SK complex and influences RNA polymerase II-mediated transcription [31]. Since SRPK activates SRSF1 through the phosphorylation of the RS domain [32], the current data suggest that SRPK inhibition by SRPIN340 may reduce transcription of *VEGF*, in addition to the switching to antiangiogenic *VEGF* isoforms.

During CNV formation, VEGF and its related molecules reciprocally accelerate angiogenesis via macrophage infiltration. For instance, VEGF induces MCP-1 and ICAM-1 production in endothelial cells, both of which play a role in macrophage recruitment [33-35], and directly mediates macrophage migration via its receptor 1 [36]. Subsequently, the recruited macrophages secrete VEGF and facilitate CNV growth [37]. Thus, decrease of VEGF might result in reduced macrophages influx and VEGF secretion. Indeed, in the current study we observed that levels of inflammation-associated molecules were decreased during CNV formation,
following VEGF downregulation via SRPK inhibition with SRPIN340. Therefore, SRPK inhibition with SRPIN340 could disrupt the vicious cycle formed by VEGF and its related proteins such as MCP-1 and ICAM-1, and result in the attenuation of CNV formation, suggesting the possibility of a novel chemical treatment strategy for pathological angiogenesis, which targets SRPK.

ACKNOWLEDGMENTS
The authors thank Ikuyo Hirose and Shicho Namba for their skillful technical assistance. This study was supported by the Advanced research for medical products Mining Programme of the National Institute of Biomedical Innovation (NIBIO) and Grant-in-Aid for Scientific Research (C: 23,592,547) of the Japan Society for the Promotion of Science.

REFERENCES
1. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44:17-39. [PMID: 15577562].
2. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36:182-91. [PMID: 7822146].
3. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007; 14:184-7. [PMID: 17896295].
4. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beaugamp GR. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol 2006; 17:257-66. [PMID: 16794438].
5. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32:375-413. [PMID: 2457955].
6. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157:135-44. [PMID: 10808384].
7. Spadea RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-90. [PMID: 16603955].
8. Gragoudas ES, Adams AP, Cunningham ET Jr, Feinsod M, Gayer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16. [PMID: 15625332].
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31. [PMID: 17021318].
10. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adams AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med 2003; 9:781-8. [PMID: 12730690].
11. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8:880-7. [PMID: 18923433].
12. Caceres JF, Kornblitht AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18:186-93. [PMID: 11932019].
13. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 121:3487-95. [PMID: 18843117].
14. Fukushima T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Herzenberg LA, Hagiwara M. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci USA 2006; 103:11329-33. [PMID: 16840555].
15. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010; 285:5532-40. [PMID: 19906640].
16. Kuroyanagi N, Onogi H, Wakabayashi T, Hagiwara M. Novel SR-protein-specific kinase, SRPK2, disassembles nuclear speckles. Biochem Biophys Res Commun 1998; 242:357-64. [PMID: 9446799].
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8. [PMID: 12073602].
18. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981; 11:805-15. [PMID: 7308288].
19. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116:362-7. [PMID: 19187826].
20. Semeraro F, Morescalchi F, Paredigiani F, Arcidiacono B, Costagliola C. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol 2011; 9:629-46. [PMID: 21470108].
21. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-85. [PMID: 17522716].
22. Cunningham ET Jr, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular...
23. Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008; 36:252-6. [PMID: 18412594].

24. Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, Mettling C, Portales P, Grierson D, Chabot B, Jeanteur P, Branlant C, Corbeau P, Tazi J. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog 2007; 3:1530-9. [PMID: 17967062].

25. Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, Kakinuma S, Ooka M, Azuma T, Tsuchiya K, Onogi H, Hagiwara M, Watanabe M. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother 2010; 54:3179-86. [PMID: 20498328].

26. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol 2007; 18:719-29. [PMID: 17267748].

27. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard D, Prasanth KV. SRSP1 regulates the assembly of pre-mRNA processing factors in nuclear speckles. Mol Biol Cell 2012; 23:3694-706. [PMID: 22855529].

28. Zheng XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 2009; 23:482-95. [PMID: 19240134].

29. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96:34-40. [PMID: 10891427].

30. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011; 20:768-80. [PMID: 22172722].

31. Tripathi V, Song DY, Zong X, Shvetsov SP, Hearn S, Fu XD, Munday M, Prasanth KV. SRSP1 regulates the assembly of pre-mRNA processing factors in nuclear speckles. Mol Biol Cell 2012; 23:3694-706. [PMID: 22855529].

32. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 2009; 23:482-95. [PMID: 19240134].

33. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96:34-40. [PMID: 10891427].

34. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adams AP. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44:2155-62. [PMID: 12714656].

35. Yoshida S, Yoshida A, Ishibashi T, Elnner SG, Elnner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postschismic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol 2003; 73:137-44. [PMID: 12525571].

36. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336-43. [PMID: 8605350].

37. Tsutsumi C, Sonoda KH, Egashira K, Qiao H, Hisatomi T, Nakao S, Ishibashi M, Charo IF, Sakamoto T, Murata T, Ishibashi T. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003; 73:137-44. [PMID: 12525571].